Capital at risk
Health Innovation
Healthcare is undergoing monumental change. Perhaps more than any other sector, it offers extreme payoffs for those seeking long-term disruptive investments. Companies developing technologies that improve outcomes for large numbers of patients can grow exponentially. Our quest is to own those rare firms for long periods while they transform the full value chain of human health.
Radical change, radical possibilities
The future of human health is radically changing. We aim to find and invest in companies that address society’s biggest problems to make healthcare more efficient and accessible and, in turn, generate strong long-term returns for our clients.
Health Innovation: our philosophy
Investment manager Julia Angeles introduces Health Innovation, reflecting on the exciting opportunities ahead.
Driving transformation
Our objective is to outperform the MSCI ACWI Index by at least 2.5 per cent (net of fees) over rolling five-year periods. We intend to achieve this by investing in companies that are driving the transformation of healthcare, from diagnosis and treatment to efficiency and access.
Our approach is agnostic to sector and benchmark composition. We aim to find and own those few companies that really matter in the theme and hold them in a concentrated portfolio of 25-50 names over the long term, generally for five years or more.
Different than the average
This is not just another healthcare sector fund. We are not restricted to the MSCI World Health Care Index – our opportunity set is much broader than that. This is a thematic fund. We are experiencing a great convergence of science and technology, and we are seeking the transformative companies at the heart of this.
That’s why we think we can offer something different. This approach isn’t new to Baillie Gifford. We have been investing in innovation since our inception in 1908, and today close to 15 per cent of our clients’ assets are invested in leading healthcare companies.
Most of the exorbitant costs of healthcare today are associated with care that is not transformative and not personalised. It’s clear that this model is unsustainable.
Meet the managers
Documents
Philosophy and process
Explore our investment process and idea generation as our Health Innovation investors believe it’s time to rethink what the term healthcare means.
Quarterly update
Get the latest investment commentary, portfolio overview, transactions and performance information alongside governance engagement and voting.
Invest in this strategy
You can invest in this strategy through the following fund(s).
Explore further
Curious to learn more about our products and what we can offer you? Please get in touch.
Strategy portfolio holdings
A list of the top 10 holdings that the representative portfolio invests in.
All figures up to: 31 August 2024
| # | Holding | % of portfolio |
|---|---|---|
| 1 | argenx | 7.3% |
| 2 | Alnylam Pharmaceuticals | 6.9% |
| 3 | ALK-Abello | 5.9% |
| 4 | Genmab | 5.1% |
| 5 | Ambu | 5.0% |
| 6 | Moderna | 4.4% |
| 7 | Novo Nordisk | 4.1% |
| 8 | ResMed | 4.0% |
| 9 | Insulet Corporation | 3.8% |
| 10 | Exact Sciences | 3.7% |
Please note
The information contained on this page is intended as a guide only and should not be relied upon when making investment decisions. All holdings information is unaudited. Source Baillie Gifford & Co. Please note that totals may not add due to rounding.
Invest in this strategy
You can invest in this strategy through the following fund(s).
Explore further
Curious to learn more about our products and what we can offer you? Please get in touch.
Insights
Key articles, videos and podcasts relating to the strategy:
Filters
Insights
AI: driving a new healthcare paradigm
Why AI could be key to us living longer and being in better health in the future.
Health Innovation Q2 update
The Health Innovation Team reflects on recent performance, portfolio changes and market developments.
Health Innovation Q1 update
The Health Innovation Team reflects on recent performance, portfolio changes and market developments.
Five years of health innovation
Investors take note: technology and innovation are revolutionising treatments and patient care.
Five years of the Health Innovation Strategy
A deep dive into five years of the Health Innovation Strategy and the progress made within healthcare.
Moderna: designing drugs on a computer
Can scientists meet unmet health needs by writing code to help the body heal itself?
Health Innovation Q4 update
The Health Innovation Team reflects on recent performance, portfolio changes and market developments.
Why growth, why now?
Tough times play to the partnership’s strengths: analysing what enables us to adapt and thrive amid rapid change.
Health Innovation Q3 update
The Health Innovation Team reflects on recent performance, portfolio changes and market developments.
Health Innovation Strategy
Investment manager, Julia Angeles, discusses the Baillie Gifford Health Innovation Strategy.
Health Innovation Q2 update
The Health Innovation team reflects on recent performance, portfolio changes, and market developments.
Sustainable investing in the health sector
The Health Innovation team on ESG, the future of medicine and making a positive global impact.
A dose of innovation
Your money or your health. Marina Record asks if society is ready to pay for health innovation.
Disrupting heart disease
Rose Nguyen on the companies seeking to overcome the scourge of heart disease.
Solving the antimicrobial crisis
If we don’t tackle the AMR crisis now, it could be the world’s biggest killer by 2050.
Transforming the future of healthcare
Supporting companies with the potential to transform the field of healthcare and generate attractive returns.
Health Innovation: impact and ESG
Why the forthcoming Health Innovation Impact Strategy should focus minds.
Investing in exceptional biotech
Drugs with fewer side effects, reprogramming the immune system and more from the Health Innovation Team.
Health Innovation: it’s time to rethink what the word ‘healthcare’ means
We are in an era of great convergence. The Health Innovation strategy seeks to support this era of change by looking out for innovative and pioneering companies that have the potential to bring substantial improvements to human health and healthcare systems.
Health Innovation Q2 update
The Health Innovation Team reflects on recent performance, portfolio changes and market developments.
AI: driving a new healthcare paradigm
Why AI could be key to us living longer and being in better health in the future.Health Innovation Q2 update
The Health Innovation Team reflects on recent performance, portfolio changes and market developments.Health Innovation Q1 update
The Health Innovation Team reflects on recent performance, portfolio changes and market developments.Five years of health innovation
Investors take note: technology and innovation are revolutionising treatments and patient care.Five years of the Health Innovation Strategy
A deep dive into five years of the Health Innovation Strategy and the progress made within healthcare.Moderna: designing drugs on a computer
Can scientists meet unmet health needs by writing code to help the body heal itself?Health Innovation Q4 update
The Health Innovation Team reflects on recent performance, portfolio changes and market developments.Why growth, why now?
Tough times play to the partnership’s strengths: analysing what enables us to adapt and thrive amid rapid change.Health Innovation Q3 update
The Health Innovation Team reflects on recent performance, portfolio changes and market developments.Health Innovation Strategy
Investment manager, Julia Angeles, discusses the Baillie Gifford Health Innovation Strategy.Health Innovation Q2 update
The Health Innovation team reflects on recent performance, portfolio changes, and market developments.Sustainable investing in the health sector
The Health Innovation team on ESG, the future of medicine and making a positive global impact.A dose of innovation
Your money or your health. Marina Record asks if society is ready to pay for health innovation.Disrupting heart disease
Rose Nguyen on the companies seeking to overcome the scourge of heart disease.Solving the antimicrobial crisis
If we don’t tackle the AMR crisis now, it could be the world’s biggest killer by 2050.Transforming the future of healthcare
Supporting companies with the potential to transform the field of healthcare and generate attractive returns.Health Innovation: impact and ESG
Why the forthcoming Health Innovation Impact Strategy should focus minds.Investing in exceptional biotech
Drugs with fewer side effects, reprogramming the immune system and more from the Health Innovation Team.Health Innovation: it’s time to rethink what the word ‘healthcare’ means
We are in an era of great convergence. The Health Innovation strategy seeks to support this era of change by looking out for innovative and pioneering companies that have the potential to bring substantial improvements to human health and healthcare systems.
Invest in this strategy
You can invest in this strategy through the following fund(s).
Explore further
Curious to learn more about our products and what we can offer you? Please get in touch.
How to invest in this strategy
You can invest in this strategy through the following fund(s).
Explore further
Curious to learn more about our products and what we can offer you? Please get in touch.
Important information
The content of this website is intended exclusively for professional investors in accordance with MiFID legislation. 'Professional investors' are potential investors who are deemed to have the status of “professional clients”, within the meaning of MiFID (2004/39/EC), as transposed in Ireland. It is not intended for retail investors.
Baillie Gifford Investment Management (Europe) Limited is authorised and regulated by the Central Bank of Ireland (Reference number C182354) as an Alternative Investment Fund Manager and UCITS Manager to Baillie Gifford Worldwide Funds plc. Its registered office is 4/5 School House Lane East, Dublin 2, D02 N279, Ireland.
This website is informative only and the information provided should not be considered as investment or other advice or a recommendation to buy, sell or hold a particular investment. Read our Legal and regulatory information for further details.